Literature DB >> 4013994

Long-acting nifedipine in moderate and severe hypertensive patients with serious concomitant diseases.

M Bursztyn, E Grossman, T Rosenthal.   

Abstract

Long-acting nifedipine tablets were given to 47 severely and moderately hypertensive patients with renal insufficiency, cardiovascular, cerebrovascular, and peripheral vascular disease, diabetes mellitus, asthma, and systemic lupus erythematosus. Nifedipine substituted vasodilators (n = 22), was added to beta blockers and thiazides (n = 14), and was used alone (n = 11). In all three groups blood pressure was significantly reduced without aggravation of angina pectoris, intermittent claudication, cerebrovascular disease, or renal failure. Side effects were mild and transient. We found nifedipine tablets convenient and safe, as well as efficacious in patients with serious conditions.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4013994     DOI: 10.1016/0002-8703(85)90521-6

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

1.  Angiotensin-converting enzyme inhibitors or calcium channel blockers? An overview.

Authors:  H Gavras
Journal:  Drugs       Date:  1990       Impact factor: 9.546

Review 2.  Sustained release nifedipine formulations. An appraisal of their current uses and prospective roles in the treatment of hypertension, ischaemic heart disease and peripheral vascular disorders.

Authors:  D Murdoch; R N Brogden
Journal:  Drugs       Date:  1991-05       Impact factor: 9.546

Review 3.  Drug therapy of renovascular hypertension.

Authors:  Talma Rosenthal
Journal:  Drugs       Date:  1993-06       Impact factor: 9.546

Review 4.  Interventions for deliberately altering blood pressure in acute stroke.

Authors:  Philip M W Bath; Kailash Krishnan
Journal:  Cochrane Database Syst Rev       Date:  2014-10-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.